After a lull, or at least a single-minded focus on femtosecond lasers for a time, refractive surgery has gotten exciting again: the drive to spectacle-free outcomes for cataract patients (who have aged-out of their eligibility for other refractive procedures) is calling for solutions that offer precision and accuracy at every stage of treatment. Start-ups coming up with the solutions will be serving some gigantic markets.
Cerora Inc. has developed a concussion assessment platform that will collect and analyze many different types of inputs: EEG data, eye gaze measurements, and measures of cognition and voice analysis, to detect concussions. By doing so, the company thinks it will be able to provide a more comprehensive picture of brain injury than competitors whose technologies assess a single factor.
Medical device start-ups are surging into new territory in mild traumatic brain injury or concussion detection, which has heretofore lacked objective diagnostics and monitoring tools. Profiles of Cerora, MC10, Oculogica, and Sway Medical.
At the end of October, Apollo Endosurgery announced that it would acquire certain obesity assets from Allergan: Lap-Band, one of the most well-known brands in bariatric surgery, and Orbera, Allergan’s intra-gastric balloon system, the leading such product in Europe. It’s not unusual these days for large companies to unload under-performing businesses, but the Allergan deal is striking because of its choice of partner. Apollo Endosurgery is a small organization acquiring a much larger one.
For therapeutic hypothermia device companies, the clinical trials that came before have been inconclusive, but they have provided insights to incorporate into the development of next-generation technologies. START-UP interviews two hypothermia device companies with novel approaches: Thermocure and ThermopeutiX.
Investors and their limited partners really don’t like risk, especially not the kind due to uncertainty. Now, for developers of mobile health applications and their investors, at least one risk has been taken off the table: regulatory uncertainty. On September 23, the FDA published the much-anticipated final guidance on mobile medical apps.
Start-ups developing technologies to help hospitals avoid preventable medical errors known as “never events” are developing solutions to nosocomial infections, retained surgical objects, pressure ulcers, and medication errors.
During insertion of central venous catheters, physicians may unintentionally advance into an artery rather than the desired vein, an error that can cause serious complications, even death. Mirador Biomedical Inc. aims to improve the safety of central venous access with its Compass platform, battery-powered, pressure-measurement devices that can rapidly detect the difference in pressures between arteries and veins.